

1 **Vascular-water-exchange MRI (VEXI) enables the detection of subtle
2 BBB breakdown in Alzheimer's disease without MRI contrast agent**

3 Yifan Zhang^{1,2#}, Yue Wang^{3,4#}, Zhaoqing Li^{1,2}, Zejun Wang^{1,2}, Juange Cheng¹, Xiaoyan Bai^{5,6}, Yi-
4 Cheng Hsu⁷, Yi Sun⁷, Shiping Li^{3,4,8}, Jiong Shi^{3,4,8*}, Binbin Sui^{3*}, Ruiliang Bai^{1,2,9*}

5 ¹Department of Physical Medicine and Rehabilitation of the Affiliated Sir Run Shaw Hospital AND
6 Interdisciplinary Institute of Neuroscience and Technology, School of Medicine, Zhejiang University,
7 Hangzhou, China

8 ²Key Laboratory of Biomedical Engineering of Education Ministry, College of Biomedical Engineering
9 and Instrument Science, Zhejiang University, Hangzhou, China

10 ³National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical
11 University, Beijing, China

12 ⁴Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

13 ⁵Tiantan Neuroimaging Center of Excellence, China National Clinical Research Center for Neurological
14 Diseases, Beijing, China

15 ⁶Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing Neurosurgical
16 Institute, Beijing, China

17 ⁷MR Collaboration, Siemens Healthcare, Shanghai, China

18 ⁸Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China

19 ⁹MOE Frontier Science Center for Brain Science and Brain-machine Integration, School of Brain Science
20 and Brain Medicine, Zhejiang University

21

22

23 # These authors make equally contribution to this manuscript.

24 ***Corresponding author:** Dr. Ruiliang Bai;

25 Address: 268 Kaixuan Road, South Central Building, Room 708, Hangzhou, Zhejiang, China,
26 310027; Phone: 0571-8697112; E-Mail: ruiliangbai@zju.edu.cn

27 Dr. Binbin Sui: Address: No.119, West Road of South 4th Ring Road, Fengtai District,
28 Beijing 100070 China; TEL: 86-10-59975392; Email: reneesui@163.com

1 Dr. Jiong Shi: Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, No.
2 119, South Fourth Ring West Road, Fengtai District, Beijing, China, 100070, Tel +86-10-59978350,
3 Fax +86-10-59973383; Email: jiongshi@ncrcnd.org.cn

4

5

6 **Abstracts**

7 Blood-brain barrier (BBB) impairment is an important pathophysiological process in Alzheimer's
8 disease (AD) and a potential biomarker for early diagnosis of AD. However, most current
9 neuroimaging methods assessing BBB function need the injection of exogenous contrast agents (or
10 tracers), which limits the application of these methods in a large population. In this study, we aim
11 to explore the feasibility of vascular water exchange MRI (VEXI), a diffusion-MRI-based method
12 to assess the BBB permeability to water molecules without using a contrast agent, in the detection
13 of the BBB breakdown in AD. We tested VEXI on a 3T MRI scanner on three groups: AD patients
14 (AD group), mild cognitive impairment (MCI) patients due to AD (MCI group), and the age-
15 matched normal cognition subjects (NC group). Interestingly, we find that VEXI can detect the BBB
16 permeability to water molecules increase in MCI and this BBB breakdown happens specifically in
17 the hippocampus. This BBB breakdown gets worse and extends to more brain regions (orbital
18 frontal cortex and thalamus) from MCI group to the AD group. Furthermore, we find that the BBB
19 breakdown of these three regions detected by VEXI is correlated significantly with impairment of
20 respective cognitive domains independent of age, sex and education. These results suggest VEXI is
21 a promising method to assess the BBB breakdown in AD.

22

23

1 **Highlights**

2 • The vascular water exchange MRI (VEXI) is a contrast-agent-free method to assess BBB
3 permeability
4 • BBB breakdown happens specifically in the hippocampus, orbital frontal cortex, and thalamus
5 in AD
6 • BBB breakdown detected by VEXI is significantly correlated with cognitive dysfunction

7

8 **Keywords**

9 Blood-brain barrier, contrast-agent-free, water exchange, Alzheimer's disease, permeability

10

11

1 1. Introduction

2 Increasing evidence has shown that blood-brain barrier (BBB) impairment is a contributing factor
3 in the pathophysiology of Alzheimer's disease (AD) (Iadecola, 2017; Sweeney et al., 2018). BBB
4 is a continuous endothelial membrane within brain microvessels that seals cell-to-cell contacts,
5 regulates the delivery of important nutrients to the brain, and prevents neuro-toxins from entering
6 the brain (Zlokovic, 2008). It also has a clearance function to remove excess substances from the
7 brain. BBB structure and function can be assessed with neuropathology in postmodern samples
8 (Arvanitakis et al., 2016; Toledo et al., 2013), neuroimaging methods (Kisler et al., 2017; Montagne
9 et al., 2015; Sweeney et al., 2018; van de Haar et al., 2017, 2016), and cerebrospinal fluid
10 biomarkers (Iturria-Medina et al., 2016; Montagne et al., 2015; Sagare et al., 2015; Sweeney et al.,
11 2018), among which only neuroimaging methods could provide the spatial distribution features of
12 BBB impairment *in vivo*. Studies using these neuroimaging methods, including positron emission
13 tomography (PET) and MRI, have produced fruitful results of increased BBB permeability in
14 different brain regions in AD patients (Minoshima et al., 1997; van de Haar et al., 2017, 2016; Wang
15 et al., 2006) and its relationship with brain structural changes (e.g. atrophy) (Nation et al., 2019;
16 Zhang et al., 2019). However, most conventionally used neuroimaging methods assessing BBB
17 permeability in AD utilize the intravenous administration of contrast agents (or radioactive tracer).
18 A non-invasive and contrast-agent-free neuroimaging method to characterize BBB permeability is
19 still highly desirable.

20

21 Recently, there are several newly developed MRI methods aiming to measure the water
22 exchange across BBB, which provides a novel means to assess BBB permeability without the usage
23 of contrast agent (Dickie et al., 2020). These contrast-agent-free MRI techniques mainly include
24 two different types of approaches. One is based on arterial spin labeling (ASL) technique, which
25 uses ASL to label intravascular water and then monitor the dynamic change of labeled water in
26 intravascular and extravascular spaces by using diffusion (He et al., 2018, 2012; Wang et al., 2007),
27 multiple echo (Ohene et al., 2019), or phase contrast (Lin et al., 2018) methods. The second
28 approach utilizes the filter-exchange imaging (FEXI), a technique adapted from diffusion exchange
29 spectroscopy (DEXSY) for clinical applications (Lasić et al., 2011; Nilsson et al., 2013). By

1 exploring the intravoxel incoherent motion (IVIM) of capillary water, designing a proper diffusion
2 weighting to filter out intravascular water specifically and then quantitatively monitoring the water
3 exchange between intra- and extravascular space via the second diffusion encoding, FEXI shows
4 the capacity for measuring the water exchange across BBB in human (Bai et al., 2020). More
5 encouragingly, a recent study shows that the water exchange across BBB is a more sensitive
6 biomarker in the detection of subtle BBB breakdown than the conventional biomarker of contrast
7 agent leakage from BBB in an AD rat model, as water molecule is much smaller than MRI contrast
8 agents and could potentially be more sensitive to BBB leakage (Dickie et al., 2019). However, it is
9 still unknown if it is feasible to use the water-exchange based MRI method to detect the BBB
10 leakage in AD patients.

11

12 In this study, we aim to explore the feasibility of the contrast-agent-free MRI method in the
13 detection of subtle BBB impairment in AD patients. For this purpose, the FEXI-based vascular-
14 water-exchange MRI (VEXI) was implemented on a 3T clinical MRI scanner to assess the BBB
15 permeability to water molecules. MRI and cognitive function assessments were performed on three
16 groups: AD patients (AD group), mild cognitive impairment due to AD patients (MCI group), and
17 the age-matched normal cognition subjects (NC group). Both MCI and AD groups were diagnosed
18 based on clinical criteria and positive amyloid-beta (A β) deposition confirmed by PET.

19

20

21 **2. Methods**

22 **2.1. Study Participants**

23 This study was a sub-study of an ongoing prospective community-based cohort study of the China
24 National Clinical Research Center Alzheimer's Disease and Neurodegenerative Disorder Research
25 (CANDOR). CANDOR was started in July 2019 and planned to enroll one thousand and five
26 hundred participants, including individuals with NC, MCI, and dementia (including AD).

27

28 This sub-study recruited participants from March 2021 to January 2022. All the AD and MCI
29 participants were recruited from Beijing Tiantan Hospital and the NC participants were recruited

1 from the local communities. Demographic information, past medical history, social and family
2 history were collected. All participants underwent detailed cognitive assessments, including the
3 battery of neuropsychological tests such as Mini-Mental State Examination (MMSE), Montreal
4 Cognitive Assessment (MoCA), Clinical Dementia Rating (CDR), Rey Auditory Verbal Learning
5 Test (RAVLT) etc., and brain MRIs. All enrolled participants for this study were (1) subjectively
6 normal in NC groups, or diagnosed as MCI due to AD or AD. The diagnosis of MCI due to AD and
7 AD was based on the National Institute on Aging-Alzheimer's Association guidelines for AD (Albert et
8 al., 2011; McKhann et al., 2011) and positive amyloid status confirmed by ¹¹C-labeled Pittsburgh
9 Compound-B (PIB) PET-CT; (2) aged 40-100 years-old, (3) had at least 3 years of elementary-
10 school education and could complete the neuropsychological tests independently; (4) had no
11 conditions known to affect cognitive function, such as alcoholism, uncontrolled depression or other
12 psychiatric disorders, Parkinson's disease, epilepsy, stroke and etc.

13

14 **2.2. Standard Protocol Approvals, Registrations, and Patient Consents**

15 This protocol was approved by the Institutional Review Board of Beijing Tiantan Hospital (approval
16 number: KY 2019-004-007) and was in accordance with relevant guidelines and regulations. Written
17 informed consent was obtained from each participant.

18

19 **2.3. Principles of vascular-water-exchange MRI (VEXI)**

20 VEXI characterizes the BBB permeability to water molecules, which is illustrated in **Figure 1**. It is
21 a specific type of diffusion-based FEXI adapted for measuring the water exchange across BBB (Bai
22 et al., 2020). Briefly, it contains three blocks, including the filter block, mixing block, and detection
23 block. The filter block is a pulsed gradient spin echo (PGSE) with diffusion weighting b_f , in which
24 b_f ($= 250 \text{ s/mm}^2$) is optimized to filter the intravascular water magnetization showing nearly one-
25 fold larger apparent diffusivity than the extravascular water magnetization due to IVIM (Le Bihan,
26 2019). After the first filter block, the remaining magnetization in the transverse plane is stored back
27 in the longitudinal direction and kept for a certain mixing time (t_m), during which water molecules
28 exchange across BBB (mixing block). Finally, the filtered and mixed magnetization is put back to
29 the transverse plane with the third 90° pulse and the apparent diffusivity (ADC') of the mixed water

1 pools is measured in the second PGSE block (detection block). A pair of identical gradients is
2 implemented before the second 90 pulse and after the third 90 pulse such that the stimulated echo
3 is formed after the second gradient and the unwanted magnetization (e.g., the inflowing blood from
4 neighboring slices) is eliminated.

5

6 In VEXI, ADC' were acquired at several t_m (more water molecule exchange across BBB in longer
7 t_m) and the apparent water exchange rate constant across BBB (AXR_{BBB}) could then be extracted
8 from $ADC'(t_m)$ signal (**Figure 1B**). Here it is assumed that the water molecules in brain tissue can
9 be separated into “slow” (s, extravascular water pool) and “fast” (f, intravascular water pool, IVIM)
10 diffusion components with apparent diffusivities D_s and D_f , and equilibrium fractional populations
11 f_s^{eq} and f_f^{eq} ($f_s^{eq} + f_f^{eq} = 1$), respectively. Water molecules are in exchange between the two water
12 pools across BBB with a water exchange rate constant k_{fs} from the intravascular to the extravascular
13 pool, and $k_{sf} = k_{fs}f_f^{eq}/f_s^{eq}$ from the extravascular to the intravascular water pool. At a fixed b_f , the
14 acquired MRI signal S is a function of the diffusion weighting in the detection block (b_d) and t_m
15 (Lasic et al., 2011; Nilsson et al., 2013),

16
$$S(b, t_m) = S'(t_m) \exp(-b ADC'(t_m)) \quad [1]$$

17 where $S'(t_m)$ takes into consideration the effects of longitudinal relaxation during t_m and the
18 apparent diffusion coefficient $ADC'(t_m)$ is determined by the two water components’ apparent
19 diffusivity and exchange rate, using an approximation that applies when b approaches zero,

20
$$ADC'(t_m) = ADC_0(1 - \sigma \exp(-t_m AXR_{BBB})) \quad [2]$$


21
$$ADC_0 = f_s^{eq}D_s + f_f^{eq}D_f \quad [3]$$

22 Here it is assumed that exchange is slow on the time scale of the duration of the PGSE blocks and
23 that longitudinal relaxation rates are the same for both components. σ is the filter efficiency that
24 quantifies the ADC' reduction at $t_m = 0$. AXR_{BBB} is the apparent water exchange rate constant
25 across BBB and its relation with the intravascular water efflux rate constant k_{fs} is,

26
$$AXR_{BBB} = k_{fs} + k_{sf} = \frac{k_{fs}}{1 - f_f^{eq}} \quad [4]$$

27 , and AXR_{BBB} approaches to k_{fs} in gray or white matter as the intravascular water fraction f_f^{eq} is
28 generally small (e.g., < 5%) in healthy brain or the degenerated brain. In this study, AXR_{BBB} is taken

1 as the quantitative parameter characterizing BBB permeability to water molecules.



2
3 Figure 1. Overview of the principles of VEXI implemented in this study. (A) VEXI pulse sequence. (B) Illustration
4 of the MRI signal evaluation of intravascular and extracellular water molecule during VEXI acquisition. The first
5 pulsed gradient spin echo (PGSE) block with diffusion weighting b_f is served as the filter of intravascular water
6 pools, which showing large apparent diffusivity due to IVIM. After the first filter block, the remaining magnetization
7 in the transverse plane is stored back in the longitudinal direction (mixing block) and kept for a certain mixing time
8 (t_m), during which water molecules exchange across BBB. Finally, the filtered and mixed magnetization is put back
9 to the transverse plane with the third 90° pulse and the apparent diffusivity (ADC') of the mixed water pools is
10 measured in the second PGSE block. In VEXI, ADC' were acquired at several t_m (more water molecules exchange
11 across BBB in longer t_m) and the apparent water exchange rate across BBB (AXR_{BBB}) could then be extracted from
12 $ADC'(t_m)$ signal.

13

14 **2.4. MRI protocols**

15 MRI scans were performed with a 3.0T MRI clinical scanner (MAGNETOM Prisma, Siemens
16 Healthcare, Erlangen, Germany), using a Nova 64-channel head RF coil. MRI scans included 3D
17 MPRAGE T_1 -weighted images, diffusion-weighted images and VEXI. The T_1 -weighted images
18 were acquired with $1.0 \times 1.0 \times 1.0 \text{ mm}^3$ resolution, $TE/TR = 2.01/2000 \text{ ms}$, flip angle 8° , inversion
19 time 880 ms . To characterize diffusion anisotropy, a diffusion tensor imaging (DTI) protocol was
20 performed with $TE/TR = 70/2800 \text{ ms}$, 5 repetitions on $b = 0 \text{ s/mm}^2$ and 50 directions with single

1 repetition for each direction at $b = 1000$ s/mm². The voxel size for the DTI images was $2.0 \times 2.0 \times$
2 2.0 mm³. VEXI was performed at XZ direction with $b_f = 250$ s/mm² and two b values in the detection
3 block ($b_d = 0$ s/mm² with 6 repetitions and 250 s/mm² with 10 repetitions). Imaging was repeated
4 with three mixing time (t_m): 25, 200, and 400 ms. VEXI was also acquired with $b_f = 0$ s/mm² and
5 shortest t_m (25 ms), echo time in the filter block $TE_f = 26$ ms, echo time in the detection block $TE =$
6 37 ms, timings of the gradients in the filter block $\Delta_f/\delta_f = 11.5$ ms / 6.3 ms, and timings of the
7 gradients in the detection block $\Delta/\delta = 14.4$ ms / 8.6 ms. For the VEXI protocol, the voxel size was
8 $3.0 \times 3.0 \times 5.0$ mm³, and the number of slices was 20.

9

10 **2.5. VEXI data processing**

11 All DTI and VEXI data underwent pre-processing including motion and eddy current distortion
12 correction in TORTOISE (Pierpaoli et al., 2010). For the DTI data, pre-processed DWIs were fit to
13 non-linear DTI model and DTI metrics including mean diffusivity (MD) were generated with
14 TORTOISE. For the VEXI data, the model fitting was performed with in-house programs developed
15 in MATLAB (2018B, The MathWorks Inc., Natick, Massachusetts). Here, the $ADC'(t_m)$ values
16 were computed from the measurements with two b values in the detection block (b_{d1} and b_{d2}) at
17 each t_m , according to

18
$$ADC'(t_m) = -\frac{1}{b_{d2}-b_{d1}} \ln\left(\frac{S(t_m, b_{d2})}{S(t_m, b_{d1})}\right) \quad [5]$$

19 where $S(t_m, b_{d1})$ and $S(t_m, b_{d2})$ are the VEXI signals acquired at b_{d1} and b_{d2} , respectively.
20 Then the $ADC'(t_m)$ at three t_m and $b_f = 0$ (taken as equilibrium state, *i.e.*, $t_m = +\text{Inf}$) were fitted to
21 Eq. [2] with the trust-region nonlinear least-squares algorithm in each voxel to calculate the VEXI
22 derived parameters, AXR_{BBB} , ADC and σ .

23

24 **2.6 Region-of-interest (ROI) analysis**

25 We then generated a study-specific template with the T_1 -weighted images of all subjects in NC
26 group, using the ANTs script (Avants et al., 2010). DTI data with $b=0$ s/mm² and VEXI data with
27 $b_f=0$ s/mm² and $b_d=0$ s/mm² were linear registered to T_1 -weighted images using ANTs (Avants et
28 al., 2011). Afterwards, the T_1 -weighted images in the native space were registered to our study-
29 specific template using ANTs SyN algorithm. Parameter maps (AXR_{BBB} , ADC and σ) were then


1 iteratively aligned to the template by applying the linear registration transformation matrix and the
2 deformation field generated above. In addition, we nonlinearly registered the MNI152 T_1 -weighted
3 template (Mazziotta et al., 2001, 1995) to our template to transform some atlas defined in MNI152
4 template into our study- specific template space.

5

6 Region-of-interest (ROI) masks were extracted from Brainnetome Atlas (Fan et al., 2016) and JHU
7 white matter Atlas (Mori et al., 2005). As shown in **Figure 2**, a total of 5 grey matter ROIs including
8 the hippocampus, caudate nucleus, thalamus, striatum, and orbital frontal cortex (OFC) and 3 white
9 matter ROIs including subcortical watershed white matter fibers, corpus callosum and internal
10 capsule were chosen according to other studies in AD or MCI (Montagne et al., 2015). All the ROIs
11 were bilateral. Several steps were implemented to reduce the potential confound induced by brain
12 atrophy, which includes (1) one experienced neurologist was invited to readjust and double-check
13 the hippocampus and other brain ROIs based on neuroanatomy, (2) the 3D structural images (T_1
14 weighted) were segmented into CSF, gray matter, and white matter, and these selected brain ROIs
15 (like hippocampus) were readjusted to remove the CSF voxels based on the segmented results; (3)
16 voxels with MD larger than $2.0 \text{ um}^2/\text{ms}$ were also considered as CSF voxels and further removed
17 from these brain ROIs. The parametric metrics in each ROI were calculated as the median of all
18 voxels in this ROI.

19

20 To double check the results obtained in the template space, the same ROI-level analysis was also
21 performed in the subjects' native space. The 8 selected brain regions were manually drawn by one
22 experienced neurologist on each subject's native space. CSF voxels were removed using the same
23 methods in the template space. The parametric metrics in each ROI were also calculated as the
24 median of all voxels in this ROI.



25
26 **Figure 2.** Eight regions of interest based on Brainnetome atlas and JHU white matter atlas in the customized-
27 template space. Here different ROIs were represented with different numbers.

1

2 **2.7 Volumetric analysis**

3 For the regional level volumetric analysis, all the T_1 -weighted images were processed through the
4 voxel-based-morphometry (VBM) pipeline in SPM12, which has been described previously
5 (Ashburner and Friston, 2000). Briefly, we created our study-specific DARTEL template based on
6 the template generated above. Then each T_1 -weighted image was segmented into GM, WM and CSF
7 using the segmentation function in SPM12. Segmented images were then aligned to the DARTEL
8 template iteratively, spatially normalized, modulated and smoothed with an 8mm Gaussian kernel.
9 Volumes for the ROIs were calculated by summing all the white and grey matter voxels in the ROI
10 from the pre-processed images. To correct for the head size, the total intracranial volume (TIV) was
11 calculated as the sum of all voxels across the grey matter, white matter, and CSF segmented images.
12 Then ROI volume was corrected by simply dividing by TIV, a widely used method for volumetric
13 correction.

14

15 **2.8 Statistics**

16 Prior to performing statistical analyses, we first screened for outliers using the Grubbs' test by
17 applying a significant level of $\alpha=0.01$ (Nation et al., 2019). All continuous variables were checked
18 for normality through examination of skewness and kurtosis. Log10-transformations were applied
19 where departures of normality were identified. Distribution normalization was confirmed before
20 parametric analyses. Unpaired Students' t-test was performed to compare the median AXR_{BBB} in
21 each ROI between NC group and MCI group. One-way analysis of variance (ANOVA) was
22 performed to explore the AXR_{BBB} change in each ROI among the three groups. One-way ANOVA
23 was also employed to assess the difference in age, education levels and the scores of neurological
24 tests, and the median ADC, σ and volume in all the ROIs among NC, MCI, and AD groups.
25 Categorical variables were analyzed by Pearson's χ^2 tests. Correlation analysis between AXR_{BBB}
26 and cognitive functions were performed with linear regressions, with age, sex and education level
27 controlled.

28 All statistical analyses were performed in GraphPad Prism8.

29

1 **3. Results**

2 **3.1 Subjects' clinical characteristics**

3 From March 2021 to January 2022, 52 participants were recruited for this sub-study from Beijing
4 Tiantan Hospital and the local communities, including 27 healthy controls, 14 with MCI due to AD
5 and 11 with AD. The baseline information of the subjects was showed in **Table 1**. There was no
6 difference in age, gender and education level among groups. Statistical significance among groups
7 was found in the neuropsychological tests, including MMSE, MoCA, CDR global scores, and
8 RAVLT. The participants in NC group showed better performance than MCI and AD groups. Here,
9 the MoCA scores seems to be lower than expected which could be presumably due to the linguistic
10 and cultural differences between the original English version and the Chinese version of the scale
11 or the lower education level of Chinese older adults (Yu et al., 2012).

12

13 **Table 1. Subject characteristics**

Variables	NC (n = 27)	MCI (n =14)	AD-Dementia (n = 11)	P
Average age, mean + SD	63.30±7.23	67.21±9.07	63.75±6.51	0.286
Gender female, n (%)	15, 55.5%	8, 57.1%	4, 36.4%	0.503
Years of education, mean ± SD	12.59±3.15	11.93±5.08	11.45±3.67	0.593
CDR global scores, mean ± SD	0	0.5	2.27±1.62	<0.001
MMSE, mean ± SD	26.07±1.88	19.86±6.3	10.09±6.43	<0.001
MoCA, mean ± SD	22.52±3.76	15.36±6.95	7.09±5.87	<0.001
RAVLT learn total, mean ± SD	37.33±9.13	25±9.33	8±10.06	<0.001
RAVLT long delayed recall, mean ± SD	6.37±3.00	2.36±3.13	0.18±0.6	<0.001

14 Abbreviations: CDR, Clinical Dementia Rating. MMSE, Mini Mental State Examination. MoCA,
15 Montreal Cognitive Assessment. RAVLT, Rey Auditory Verbal Learning Test. P values were calculated
16 either with One-way ANOVA or Pearson's χ^2 tests


17 .

18

19 **3.2. MCI shows increased BBB permeability in hippocampus**

20 **Figure 3** showed VEXI results of hippocampus in MCI and NC groups. Comparing with that in NC
21 group, the apparent diffusion coefficient *ADC*' of hippocampus in MCI showed larger values at each


1 mixing time t_m and recovered faster as t_m increased (**Figure 3A&3B**), in which the latter suggests
 2 faster water exchange across BBB (*i.e.*, increased BBB permeability, **Figure 3B**). Further
 3 quantitative modeling (**Eq. 1–3**) revealed that the AXR_{BBB} of hippocampus in MCI group ($n = 14$,
 4 group-averaged $AXR_{BBB} = 1.63 \text{ s}^{-1}$) was significantly larger than those in NC group ($n = 27$, AXR_{BBB}
 5 = 1.21 s^{-1} , $p = 0.042$, **Figure 3C**). Besides the hippocampus, no significant BBB changes between
 6 NC and MCI group were found in other cortical, subcortical or WM regions.



7 **Figure 3.** VEXI showed BBB breakdown of hippocampus in MCI group. (A) the averaged ADC' maps of all subjects
 8 in the MCI group and NC group at each mixing time. Here only the results in hippocampus were shown in color. (B)
 9 Representative $ADC'(t_m)$ curves of the hippocampus in the NC (left) and MCI (right) group were shown. Here the
 10 first circle at $t_m < 0 \text{ s}$ denoted as the equilibrium state ($b_f = 0 \text{ s/mm}^2$). (C) Statistical comparison of AXR_{BBB}
 11 between NC and MCI in hippocampus. Unpaired Students' t -test. * $p < 0.05$. NC, normal cognition group ($n=27$);
 12 MCI, mild cognitive impairment group ($n=14$).
 13

14
 15 **3.3. The BBB breakdown gets worse and extends to more brain regions from MCI to AD**
 16 To investigate the BBB integrity as the disease progresses, we further analyzed the AXR_{BBB} change
 17 from NC to MCI, and then to AD. **Figure 4A-C** showed the averaged AXR_{BBB} maps of all subjects
 18 in NC, MCI, and AD groups. In hippocampus, we found increased AXR_{BBB} as the disease
 19 progressed from MCI to AD (**Figure 4A**), suggesting more damage of BBB with severe cognitive
 20 dysfunction. Further ANOVA analyses revealed significant AXR_{BBB} changes in the hippocampus (F

1 = 4.75, $p = 0.013$, **Figure 4D**), which increased by 56.2% from NC to AD ($p = 0.016$, Tukey's post
2 hoc test). In addition, the BBB permeability showed spatial patterns inside the hippocampus: the
3 subregions close to CA1 showed the earliest AXR_{BBB} changes from NC to MCI. Due to the low
4 spatial resolution of the current VEXI method, we didn't pursue further quantitative analysis of
5 hippocampal subregions. In addition to hippocampus, thalamus and OFC also showed significantly
6 increasing AXR_{BBB} (by 59.4% and 130.0%, respectively) from NC to AD ($p = 0.0006$ and $p = 0.0001$,
7 respectively, Tukey's post hoc test after ANOVA analysis) but didn't show detectable BBB
8 permeability changes from NC to MCI even in the unpaired Students' t test (**Figure 4E&4F**).



9
10 **Figure 4.** VEXI showed BBB breakdown along with disease progression. (A-C) Averaged AXR_{BBB} maps of all
11 subjects in the NC, MCI and AD groups in hippocampus, thalamus and OFC in the template space. Statistical
12 comparison of AXR_{BBB} values in hippocampus (D), thalamus (E) , and OFC (F) among the NC (n=27), MCI (n=14)
13 and AD (n=11) groups. p , significance by ANOVA followed by Tukey's post hoc tests. * $p < 0.05$, ** $p < 0.01$, ***
14 $p < 0.001$. NC, normal cognition group; MCI, mild cognitive impairment group; AD, Alzheimer's disease.

15
16 To eliminate the potential impact of different sex composition between AD and NC (though not
17 significant), we performed permutation test by randomly choosing 7 females out of 15 in the NC
18 group to ensure the NC group has roughly the same sex ratio as the AD group. Among all the 6435

1 combinations, 100% of them in thalamus and OFC and 94.6% of them in hippocampus showed
2 significantly smaller AXR_{BBB} than the AD group ($p < 0.05$, unpaired Students' t-test), demonstrating
3 the above results were not biased by the sex composition variance.

4

5 Hippocampal atrophy is a well-established biomarker in AD. In this study, we also found the
6 significant reduction of hippocampus volume from NC to MCI and from MCI to AD. In fact, all the
7 selected brain regions showed significant volume reduction in the AD group (**Figure S1**). To further
8 demonstrate that our AXR_{BBB} results in the template space were not affected by the brain
9 morphology changes and these registration steps from subject's native space to template space, the
10 same ROI-based VEXI parameter analysis were also performed in the subjects' native space (see
11 methods). The hippocampus and other brain ROIs in each subject were manually drawn by one
12 experienced neurologist and the CSF voxels were also carefully removed. Further ANOVA test on
13 the three groups found significant differences in AXR_{BBB} only on the same three brain regions
14 (hippocampus, thalamus, and OFC) (Supplementary Information **Figure S2**). These results agree
15 with the findings in the template space (Figure 4) and further demonstrates the reliability of our
16 results in the template space.


17

18

19 **3.4. Correlation between BBB breakdown and cognitive dysfunction**

20 Linear regressions were used to assess potential correlations between BBB impairment and
21 cognitive dysfunction in all subjects and subjects except AD group. As shown in **Figure 5** although
22 the AXR_{BBB} of all the three brain regions showed significant and negative correlations with the
23 MoCA score in all subjects ($r = -0.44, p = 0.001$ in hippocampus, $r = -0.50, p = 0.0002$ in thalamus
24 and $r = -0.53, p < 0.0001$ in OFC), only in hippocampus this correlation remained significant in the
25 absence of AD group ($r = -0.32, p = 0.043$), suggesting that the worse cognitive function is
26 associated with larger hippocampal BBB impairment while the BBB impairment is related to
27 cognitive dysfunction in thalamus and OFC only at a late stage of the disease. Further statistics
28 revealed that the AXR_{BBB} of hippocampus, thalamus, and OFC in all subjects are all significantly
29 associated with cognitive performance, such as MMSE, MoCA, RAVLT learn total and RAVLT long

1 delayed recall, independent of age, sex and education (**Table 2**). We also did the correlation analysis
 2 between AXR_{BBB} of the three brain regions and other neurological tests in the absent of AD group.
 3 Similar as the above MoCA result, only in hippocampus the correlations remained significant or
 4 close to significant (except for RAVLT long delayed recall) (**Table S1**).



5
 6 **Figure 5.** Larger AXR_{BBB} was found to be associated with lower MoCA score in hippocampus(A), thalamus(B) and
 7 orbital frontal cortex(C). However, in the absence of AD data, the correlation between AXR_{BBB} and MoCA only
 8 remained in hippocampus. Here each dot denoted the data from each subject (black for NC and MCI, blue for AD).
 9 The solid and dotted line denoted the linear regression results in all the data and in the absence of AD data,
 10 respectively, along with the correlation coefficients (and p values) labeled after solid and dotted lines.

11
 12

13 **Table 2 Linear regression of BBB impairment and cognitive performance**

Variable	Hippocampus AXR _{BBB}			OFC AXR _{BBB}			Thalamus AXR _{BBB}		
	B	95% CI	p	B	95% CI	p	B	95% CI	p
MMSE	-4.98	[-7.91, -2.05]	0.001	-2.71	[-3.92, -1.50]	<0.001	-6.56	[-10.07, -3.05]	<0.001
MoCA	-5.80	[-8.68, -2.92]	<0.001	-2.49	[-3.91, -1.38]	<0.001	-6.42	[-9.97, -2.88]	0.001
RAVLT total learning	-8.84	[-14.41, -3.28]	0.002	-4.16	[-6.56, -1.76]	0.001	-14.09	[-20.35, -7.83]	<0.001
RAVLT long DR	-1.62	[-3.06, -0.18]	0.028	-0.69	[-1.32, -0.07]	0.031	-2.02	[-3.79, -0.26]	0.025


14 MMSE, Minimum Mental State Examination. MoCA, Montreal Cognitive Assessment. RAVLT, Rey Auditory
 15 Verbal Learning Test. DR, delayed recall. B, unstandardized regression coefficient. CI, confidence interval.

16

17 **3.5. Changes in other VEXI metrics along the progression of AD**

1 Significant increase in ADC_0 was found as the disease progress in hippocampus, thalamus, and OFC
2 (**Figure 6A-6C**). ANOVA analyses revealed significant ADC_0 changes in the hippocampus ($F =$
3 14.93, $p < 0.0001$, **Figure 6A**), which increased by 44.2% from NC to AD ($p < 0.0001$, Tukey's
4 post hoc test). OFC showed the similar patterns from NC to AD with ADC_0 increased by 16.4%
5 (ANOVA test, $F = 7.37$, $p = 0.0016$, **Figure 6C**). In thalamus, significant ADC_0 increase was found
6 from NC to MCI by 6% though no increase was found from MCI to AD ($F = 4.65$, $p = 0.014$, **Figure**
7 **6B**). All the other 5 brain ROIs, including caudate, striatum, IC, CC, and WSWM, also showed
8 significant ADC_0 increases from NC to AD (**Figure S3**). As for filter efficiency σ , significant
9 decreases in σ from NC to AD were only found in thalamus (**Figure 6E**) and caudate nucleus
10 (**Figure S3**). No significant changes in σ were found in other brain regions.

11



12

13 **Figure 6. Changes in the other VEXI metrics, ADC_0 and σ , along the progression of AD.** Significant ADC_0
14 increase was found in hippocampus (A), thalamus (B), and OFC (C) in the progression of AD. No significant σ
15 changes were found in hippocampus (D) and OFC (F), meanwhile thalamus (E) shows a significant decrease from
16 NC to AD. p , significance by ANOVA followed by Tukey's post hoc tests. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.
17 NC, normal cognition group (n=27); MCI, mild cognitive impairment group (n=14); AD, Alzheimer's disease (n=11).

18

1

2 **4. Discussion**

3 BBB breakdown is an essential pathophysiological process in AD and leads to the accumulation of
4 potentially neurotoxic blood-derived products in the brain that normally do not go across BBB.
5 Most neuroimaging studies that assessing BBB integrity in AD need the administration of a contrast
6 agent to characterize the vascular leakage of the contrast agent. In this study, we first assessed the
7 feasibility of vascular water exchange imaging (VEXI), a special diffusion MRI method assessing
8 the speed of water exchange across BBB without the requirement of contrast agent, in detecting the
9 BBB breakdown in AD. We found VEXI could detect the subtle BBB breakdown in the MCI group
10 in comparison with NC, which specifically happened in the hippocampus. We then found BBB
11 breakdown got worse from MCI to AD and extended to the thalamus and OFC regions. Furthermore,
12 the BBB permeability to water detected by VEXI showed a significant correlation with the cognitive
13 dysfunction. Taken together, our results have demonstrated the feasibility of VEXI in the detection
14 of BBB breakdown in AD and VEXI as a potential contrast-free neuroimaging method in the long-
15 term studies of a large population.

16

17 Hippocampus, a region critical for learning and memory, shows BBB breakdown in aging and early
18 AD (Sweeney et al., 2018). It has been demonstrated that BBB breakdown is an early event in aging
19 human brain that begins in the hippocampus using dynamic-contrast enhanced MRI (DCE-MRI)
20 and this BBB breakdown is correlated with injury to BBB associated pericytes and may contribute
21 to cognitive impairment (Montagne et al., 2015). In AD patients, BBB breakdown in hippocampus
22 was detected by using DCE-MRI methods and shown as an early sign of cognitive dysfunction
23 independent of A β and/or tau changes (Nation et al., 2019) but related to APOE4 (Montagne et al.,
24 2020). In this study, we have also found faster water exchange across BBB (i.e., AXR_{BBB}) in the
25 hippocampus in AD, which demonstrates the BBB breakdown in the hippocampus and agrees with
26 these literatures. More importantly, the BBB breakdown in the hippocampus detected in VEXI
27 correlates with cognitive dysfunction and this correlation remains in the absence of AD data,
28 suggesting its potential value as a biomarker of cognitive impairment even in the early AD phase.

29

1 In this study, we have also demonstrated the BBB breakdown of the OFC in AD, which is in line
2 with the previous studies using DCE-MRI methods (van de Haar et al., 2017, 2016). The orbital
3 frontal cortex is a region involved in awareness and metacognitive processes, in line with an
4 abundant literature (McGlynn and Schacter, 1989). Studies with PET (Salmon et al., 2006) and
5 SPECT (Mimura and Yano, 2006) have already reported a link between anosognosia in AD and
6 OFC dysfunction. A previous research has shown a significant loss of pericytes in the frontal cortex
7 in AD patients, which is correlated with BBB leakage (Sengillo et al., 2013).

8

9 In the comparison between AD and NC, the thalamus also showed significant BBB breakdown using
10 VEXI, which is not reported in recent DCE-MRI studies (Montagne et al., 2020, 2015; Nation et al.,
11 2019). This is not surprising as a previous study on AD rat model found that water exchange across
12 BBB was a more sensitive biomarker than the vascular leakage of MRI contrast agent (e.g., transfer
13 constant K^{trans}) in the detection of subtle BBB breakdown (Dickie et al., 2019). Since water molecule
14 is much smaller than contrast agent molecule, the biomarker of water exchange across BBB showed
15 BBB breakdown in several brain regions (including hippocampus, thalamus, and cortex) in this AD
16 rat model while K^{trans} failed to detect any BBB breakdown (Dickie et al., 2019). Indeed, some other
17 studies using DCE-MRI have also reported the BBB leakage in deep gray matter and cortex (van de
18 Haar et al., 2017). Thalamus, once viewed as passively receiving information from the basal ganglia
19 limbic system and cerebellum, then relaying information to the cerebral cortex, is becoming
20 increasingly acknowledged as actively regulating the information transmitted to cortical areas (B.
21 et al., 2013). Evidence reveals that lesions to higher-order thalamic areas, such as the pulvinar and
22 mediodorsal nucleus, can produce severe attention and memory deficits (Baxter, 2013; Bradfield et
23 al., 2013), suggesting an important role for the thalamus in cognition. Recent studies have also
24 shown the atrophy of thalamus in AD, which has also been proven in this study, and its potential
25 role in the cognitive dysfunction (De Jong et al., 2008; Pardilla-Delgado et al., 2021).

26

27 For the other VEXI metrics, ADC_0 shows significant increases along the progression of AD in all
28 the selected brain regions, which agrees with the observed mean diffusivity (MD) or apparent
29 diffusion coefficient (ADC) in MCI (or AD) in comparison with NC in previous studies (Altamura

1 et al., 2016; Kantarci et al., 2005; Scola et al., 2010; Takahashi et al., 2017) . Hippocampal ADC
2 has been demonstrated as an effective predictor of the conversion from amnestic MCI to
3 AD(Kantarci et al., 2005). Beyond hippocampus, a further study has also found the MD increase in
4 the whole brain and some manually segmented ROIs along the trajectory from NC to MCI and to
5 AD (Scola et al., 2010). The filter efficiency σ is a more complex parameter, which can be affected
6 by the vascular water mole fraction and the ADCs of water in both intra- and extra-vascular space
7 (see Eq. 5 in Bai et al., 2020). Both global and regional cerebra hypoperfusion has been
8 demonstrated in AD and during the preclinical phase of AD (i.e., MCI) (Austin et al., 2011;
9 Binnewijzend et al., 2016).Hypoperfusion could result to decreased ADC of intravascular water
10 and/or decreased vascular water mole fraction (Le Bihan, 2019; Zhu et al., 2020). These factors,
11 along with the increased ADC of extravascular water could explain the decreased σ in some brain
12 regions from NC to AD, though most regions don't show significant changes. However, conflict
13 results have also been reported. In a recent study using IVIM-DWI method, the detected vascular
14 water mole fraction was found to increase with cognitive decline (Bergamino et al., 2020). The good
15 news is that these two VEXI metrics are independent from AXR_{BBB} estimation (Eq. 4) and the
16 changes in ADC_0 or σ will not affect the accuracy of AXR_{BBB} estimation.

17
18 Several limitations and future works of this study should be clarified. At first, though previous study
19 has demonstrated the increased BBB permeability to water is associated with the reduced expression
20 of the tight junction protein occludin in AD rat model (Dickie et al., 2019) and CSF A β 42
21 concentration levels in healthy older human adults (Gold et al., 2021), it is still highly desired to
22 provide further pathophysiological explanations of the increased BBB permeability to water
23 molecule in human AD. For instance, CSF levels of soluble platelet-derived growth factor receptor
24 β (sPDGFR β) are one of the markers to assess the BBB-associated pericytes that play a key role in
25 maintaining the BBB integrity (Sagare et al., 2015) and can be used to compare with the VEXI
26 results in future. Another limitation is the small sample size, though careful statistics were
27 performed. It is highly desired to test VEXI in a large sample and in longitudinal studies. Third,
28 AXR_{BBB} could potentially be biased from intravascular water efflux rate constant k_{fs} by the
29 difference in vessel density among different groups (Eq. 4), but this bias (<5%, Bai et al., 2020) is

1 negligible in comparison with the relatively large AXR_{BBB} changes among different groups (>30%).
2 Forth, the current VEXI still suffers from low spatial resolution, which limits further analysis on the
3 subregions of hippocampus, thalamus, and other brain regions. Improving the spatial resolution of
4 VEXI without scarifying the signal-to-noise quality is warranted in future studies. At last, it is
5 interesting to study the age-dependence of the BBB permeability to water molecules using the same
6 MRI method (e.g., VEXI) in future. Due to the acquisition parameter differences between this study
7 and our previous work on young and healthy subjects (Bai et al., 2020), it is hard to compare the
8 results in these two studies directly.

9

10 **Acknowledgments**

11 We would like to thank all the subjects for their participation in the study. We appreciate the
12 help and work of all related clinicians, statisticians, imaging technicians and coordinators who
13 participated in this study. This study is supported by grants from National Natural Science
14 Foundation of China (NSFC) (Grant No. 81873894, Grant No. 82111530201), Beijing Municipal
15 Science & Technology Commission (Grant No. Z181100001518005), Natural Science
16 Foundation of Zhejiang Province, China (Grant No. LR20H180001), Strategic Priority Research
17 Program of the Chinese Academy of Sciences (XDB39000000), and the MOE Frontier Science
18 Center for Brain Science & Brain-Machine Integration, Zhejiang University.

19

20

References

1 Albert, M.S., DeKosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., Gamst, A.,
2 Holtzman, D.M., Jagust, W.J., Petersen, R.C., Snyder, P.J., Carrillo, M.C., Thies, B., Phelps, C.H., 2011. The diagnosis of mild cognitive impairment due to Alzheimer's disease:
3 Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on
4 diagnostic guidelines for Alzheimer's disease. *Alzheimer's Dement.*
5 <https://doi.org/10.1016/j.jalz.2011.03.008>

6 Altamura, C., Scrascia, F., Quattrocchi, C.C., Errante, Y., Gangemi, E., Curcio, G., Ursini, F.,
7 Silvestrini, M., Maggio, P., Zobel, B.B., Rossini, P.M., Pasqualetti, P., Falsetti, L., Vernieri, F.,
8 2016. Regional MRI diffusion, white-matter hyperintensities, and cognitive function in
9 Alzheimer's disease and vascular dementia. *J. Clin. Neurol.*
10 <https://doi.org/10.3988/jcn.2016.12.2.201>

11 Arvanitakis, Z., Capuano, A.W., Leurgans, S.E., Bennett, D.A., Schneider, J.A., 2016. Relation of
12 cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people:
13 a cross-sectional study. *Lancet Neurol.* [https://doi.org/10.1016/S1474-4422\(16\)30029-1](https://doi.org/10.1016/S1474-4422(16)30029-1)

14 Ashburner, J., Friston, K.J., 2000. Voxel-based morphometry - The methods. *Neuroimage.*
15 <https://doi.org/10.1006/nimg.2000.0582>

16 Austin, B.P., Nair, V.A., Meier, T.B., Xu, G., Rowley, H.A., Carlsson, C.M., Johnson, S.C.,
17 Prabhakaran, V., 2011. Effects of hypoperfusion in Alzheimer's disease. *Adv. Alzheimer's Dis.*
18 <https://doi.org/10.3233/978-1-60750-793-2-253>

19 Avants, B.B., Tustison, N.J., Song, G., Cook, P.A., Klein, A., Gee, J.C., 2011. A reproducible
20 evaluation of ANTs similarity metric performance in brain image registration. *Neuroimage.*
21 <https://doi.org/10.1016/j.neuroimage.2010.09.025>

22 Avants, B.B., Yushkevich, P., Pluta, J., Minkoff, D., Korczykowski, M., Detre, J., Gee, J.C., 2010. The
23 optimal template effect in hippocampus studies of diseased populations. *Neuroimage.*
24 <https://doi.org/10.1016/j.neuroimage.2009.09.062>

25 B., Z., Y., L., Z., N., A., H., Y., P., W., L., W., X., Z., T., J., 2013. Impaired functional connectivity
26 of the thalamus in Alzheimer's disease and mild cognitive impairment: A resting-state fMRI
27 study. *Curr. Alzheimer Res.*

28 Bai, R., Li, Z., Sun, C., Hsu, Y., Liang, H., Basser, P., 2020. Feasibility of filter-exchange imaging
29 (FEXI) in measuring different exchange processes in human brain. *Neuroimage* 219, 117039.
30 <https://doi.org/10.1016/j.neuroimage.2020.117039>

31 Baxter, M.G., 2013. Mediodorsal thalamus and cognition in nonhuman primates. *Front. Syst. Neurosci.*
32 <https://doi.org/10.3389/fnsys.2013.00038>

33 Bergamino, M., Nespodzany, A., Baxter, L.C., Burke, A., Caselli, R.J., Sabbagh, M.N., Walsh, R.R.,
34 Stokes, A.M., 2020. Preliminary Assessment of Intravoxel Incoherent Motion Diffusion-
35 Weighted MRI (IVIM-DWI) Metrics in Alzheimer's Disease. *J. Magn. Reson. Imaging.*
36 <https://doi.org/10.1002/jmri.27272>

37 Binnewijzend, M.A.A., Benedictus, M.R., Kuijer, J.P.A., van der Flier, W.M., Teunissen, C.E., Prins,
38 N.D., Wattjes, M.P., van Berckel, B.N.M., Scheltens, P., Barkhof, F., 2016. Cerebral perfusion in
39 the predementia stages of Alzheimer's disease. *Eur. Radiol.* <https://doi.org/10.1007/s00330-015-3834-9>

40 41 42 Bradfield, L.A., Hart, G., Balleine, B.W., 2013. The role of the anterior, mediodorsal, and

1 parafascicular thalamus in instrumental conditioning. *Front. Syst. Neurosci.*
2 <https://doi.org/10.3389/fnsys.2013.00051>

3 De Jong, L.W., Van Der Hiele, K., Veer, I.M., Houwing, J.J., Westendorp, R.G.J., Bollen, E.L.E.M.,
4 De Bruin, P.W., Middelkoop, H.A.M., Van Buchem, M.A., Van Der Grond, J., 2008. Strongly
5 reduced volumes of putamen and thalamus in Alzheimer's disease: An MRI study. *Brain.*
6 <https://doi.org/10.1093/brain/awn278>

7 Dickie, B.R., Parker, G.J.M., Parkes, L.M., 2020. Measuring water exchange across the blood-brain
8 barrier using MRI. *Prog. Nucl. Magn. Reson. Spectrosc.*
9 <https://doi.org/10.1016/j.pnmrs.2019.09.002>

10 Dickie, B.R., Vandesquille, M., Ulloa, J., Boutin, H., Parkes, L.M., Parker, G.J.M., 2019. Water-
11 exchange MRI detects subtle blood-brain barrier breakdown in Alzheimer's disease rats.
12 *Neuroimage* 184, 349–358. <https://doi.org/10.1016/j.neuroimage.2018.09.030>

13 Fan, L., Li, H., Zhuo, J., Zhang, Y., Wang, J., Chen, L., Yang, Z., Chu, C., Xie, S., Laird, A.R., Fox,
14 P.T., Eickhoff, S.B., Yu, C., Jiang, T., 2016. The Human Brainnetome Atlas: A New Brain Atlas
15 Based on Connectional Architecture. *Cereb. Cortex.* <https://doi.org/10.1093/cercor/bhw157>

16 Gold, B.T., Shao, X., Sudduth, T.L., Jicha, G.A., Wilcock, D.M., Seago, E.R., Wang, D.J.J., 2021.
17 Water exchange rate across the blood-brain barrier is associated with CSF amyloid- β 42 in
18 healthy older adults. *Alzheimer's Dement.* <https://doi.org/10.1002/alz.12357>

19 He, X., Raichle, M.E., Yablonskiy, D.A., 2012. Transmembrane dynamics of water exchange in human
20 brain. *Magn. Reson. Med.* <https://doi.org/10.1002/mrm.23019>

21 He, X., Wengler, K., Schweitzer, M.E., 2018. Diffusion sensitivity of 3D-GRASE in arterial spin
22 labeling perfusion. *Magn. Reson. Med.* <https://doi.org/10.1002/mrm.27058>

23 Iadecola, C., 2017. The Neurovascular Unit Coming of Age: A Journey through Neurovascular
24 Coupling in Health and Disease. *Neuron.* <https://doi.org/10.1016/j.neuron.2017.07.030>

25 Iturria-Medina, Y., Sotero, R.C., Toussaint, P.J., Mateos-Pérez, J.M., Evans, A.C., Weiner, M.W.,
26 Aisen, P., Petersen, R., Jack, C.R., Jagust, W., Trojanowski, J.Q., Toga, A.W., Beckett, L., Green,
27 R.C., Saykin, A.J., Morris, J., Shaw, L.M., Khachaturian, Z., Sorensen, G., Kuller, L., Raichle, M.,
28 Paul, S., Davies, P., Fillit, H., Hefti, F., Holtzman, D., Mesulam, M. Marcel, Potter, W.,
29 Snyder, P., Schwartz, A., Montine, T., Thomas, R.G., Donohue, M., Walter, S., Gessert, D.,
30 Sather, T., Jiminez, G., Harvey, D., Bernstein, M., Fox, N., Thompson, P., Schuff, N., Borowski, B.,
31 Gunter, J., Senjem, M., Vemuri, P., Jones, D., Kantarci, K., Ward, C., Koeppe, R.A., Foster, N.,
32 Reiman, E.M., Chen, K., Mathis, C., Landau, S., Cairns, N.J., Householder, E., Taylor-Reinwald, L.,
33 Lee, V., Korecka, M., Figurski, M., Crawford, K., Neu, S., Foroud, T.M., Potkin, S., Shen, L.,
34 Faber, K., Kim, S., Nho, K., Thal, L., Buckholtz, N., Albert, Marylyn, Frank, R., Hsiao, J.,
35 Kaye, J., Quinn, J., Lind, B., Carter, R., Dolen, S., Schneider, L.S., Pawluczyk, S., Beccera, M.,
36 Teodoro, L., Spann, B.M., Brewer, J., Vanderswag, H., Fleisher, A., Heidebrink, J.L., Lord, J.L.,
37 Mason, S.S., Albers, C.S., Knopman, D., Johnson, Kris, Doody, R.S., Villanueva-Meyer, J.,
38 Chowdhury, M., Rountree, S., Dang, M., Stern, Y., Honig, L.S., Bell, K.L., Ances, B., Carroll, M.,
39 Leon, S., Mintun, M.A., Schneider, S., Oliver, A., Marson, D., Griffith, R., Clark, D., Geldmacher, D.,
40 Brockington, J., Roberson, E., Grossman, H., Mitsis, E., De Toledo-Morrell, L., Shah, R.C., Duara, R.,
41 Varon, D., Greig, M.T., Roberts, P., Albert, Marilyn, Onyike, C., D'Agostino, D., Kielb, S., Galvin, J.E.,
42 Cerbone, B., Michel, C.A., Rusinek, H., De Leon, M.J., Glodzik, L., De Santi, S., Doraiswamy, P.M.,
43 Petrella, J.R., Wong, T.Z., Arnold, S.E., Karlawish, J.H., Wolk, D., Smith, C.D., Jicha, G., Hardy, P.,
44 Sinha, P., Oates, E.,

1 Conrad, G., Lopez, O.L., Oakley, M., Simpson, D.M., Porsteinsson, A.P., Goldstein, B.S.,
2 Martin, K., Makino, K.M., Ismail, M.S., Brand, C., Mulnard, R.A., Thai, G., Mc-Adams-Ortiz,
3 C., Womack, K., Mathews, D., Quiceno, M., Diaz-Arrastia, R., King, R., Weiner, M., Martin-
4 Cook, K., DeVous, M., Levey, A.I., Lah, J.J., Cellar, J.S., Burns, J.M., Anderson, H.S.,
5 Swerdlow, R.H., Apostolova, L., Tingus, K., Woo, E., Silverman, D.H.S., Lu, P.H., Bartzokis,
6 G., Graff-Radford, N.R., Parfitt, F., Kendall, T., Johnson, H., Farlow, M.R., Hake, A., Matthews,
7 B.R., Herring, S., Hunt, C., Van Dyck, C.H., Carson, R.E., MacAvoy, M.G., Chertkow, H.,
8 Bergman, H., Hosein, C., Black, S., Stefanovic, B., Caldwell, C., Hsiung, G.Y.R., Feldman, H.,
9 Mudge, B., Assaly, M., Kertesz, A., Rogers, J., Bernick, C., Munic, D., Kerwin, D., Mesulam,
10 Marek Marsel, Lipowski, K., Wu, C.K., Johnson, N., Sadowsky, C., Martinez, W., Villena, T.,
11 Turner, R.S., Johnson, Kathleen, Reynolds, B., Sperling, R.A., Johnson, K.A., Marshall, G.,
12 Frey, M., Lane, B., Rosen, A., Tinklenberg, J., Sabbagh, M.N., Belden, C.M., Jacobson, S.A.,
13 Sirrel, S.A., Kowall, N., Killiany, R., Budson, A.E., Norbash, A., Johnson, P.L., Allard, J.,
14 Lerner, A., Ogracki, P., Hudson, L., Fletcher, E., Carmichael, O., Olichney, J., DeCarli, C.,
15 Kittur, S., Borrie, M., Lee, T.Y., Bartha, R., Johnson, S., Asthana, S., Carlsson, C.M., Potkin,
16 S.G., Preda, A., Nguyen, D., Tariot, P., Reeder, S., Bates, V., Capote, H., Rainka, M., Scharre,
17 D.W., Kataki, M., Adeli, A., Zimmerman, E.A., Celmins, D., Brown, A.D., Pearlson, G.D.,
18 Blank, K., Anderson, K., Santulli, R.B., Kitzmiller, T.J., Schwartz, E.S., Sink, K.M., Williamson,
19 J.D., Garg, P., Watkins, F., Ott, B.R., Querfurth, H., Tremont, G., Salloway, S., Malloy, P.,
20 Correia, S., Rosen, H.J., Miller, B.L., Mintzer, J., Spicer, K., Bachman, D., Finger, E., Pasternak,
21 S., Rachinsky, I., Drost, D., Pomara, N., Hernando, R., Sarrael, A., Schultz, S.K., Ponto, L.L.B.,
22 Shim, H., Smith, K.E., Relkin, N., Chaing, G., Raudin, L., Smith, A., Fargher, K., Raj, B.A.,
23 Neylan, T., Grafman, J., Davis, M., Morrison, R., Hayes, J., Finley, S., Friedl, K., Fleischman,
24 D., Arfanakis, K., James, O., Massoglia, D., Fruehling, J.J., Harding, S., Peskind, E.R., Petrie,
25 E.C., Li, G., Yesavage, J.A., Taylor, J.L., Furst, A.J., 2016. Early role of vascular dysregulation
26 on late-onset Alzheimer's disease based on multifactorial data-driven analysis. *Nat. Commun.*
27 <https://doi.org/10.1038/ncomms11934>

28 Kantarci, K., Petersen, R.C., Boeve, B.F., Knopman, D.S., Weigand, S.D., O'Brien, P.C., Shiung,
29 M.M., Smith, G.E., Ivnik, R.J., Tangalos, E.G., Jack, C.R., 2005. DWI predicts future
30 progression to Alzheimer disease in amnestic mild cognitive impairment. *Neurology*.
31 <https://doi.org/10.1212/01.WNL.0000153076.46126.E9>

32 Kisler, K., Nelson, A.R., Montagne, A., Zlokovic, B. V., 2017. Cerebral blood flow regulation and
33 neurovascular dysfunction in Alzheimer disease. *Nat. Rev. Neurosci.*
34 <https://doi.org/10.1038/nrn.2017.48>

35 Lasić, S., Nilsson, M., Lätt, J., Ståhlberg, F., Topgaard, D., 2011. Apparent exchange rate mapping
36 with diffusion MRI. *Magn. Reson. Med.* 66, 356–365. <https://doi.org/10.1002/mrm.22782>

37 Le Bihan, D., 2019. What can we see with IVIM MRI? *Neuroimage*.
38 <https://doi.org/10.1016/j.neuroimage.2017.12.062>

39 Lin, Z., Li, Y., Su, P., Mao, D., Wei, Z., Pillai, J.J., Moghekar, A., van Osch, M., Ge, Y., Lu, H., 2018.
40 Non-contrast MR imaging of blood-brain barrier permeability to water. *Magn. Reson. Med.*
41 <https://doi.org/10.1002/mrm.27141>

42 Mazziotta, J., Toga, A., Evans, A., Fox, P., Lancaster, J., Zilles, K., Woods, R., Paus, T., Simpson, G.,
43 Pike, B., Holmes, C., Collins, L., Thompson, P., MacDonald, D., Iacoboni, M., Schormann, T.,
44 Amunts, K., Palomero-Gallagher, N., Geyer, S., Parsons, L., Narr, K., Kabani, N., Le Goualher,

1 G., Boomsma, D., Cannon, T., Kawashima, R., Mazoyer, B., 2001. A probabilistic atlas and
2 reference system for the human brain: International Consortium for Brain Mapping (ICBM).
3 Philos. Trans. R. Soc. B Biol. Sci. <https://doi.org/10.1098/rstb.2001.0915>

4 Mazziotta, J.C., Toga, A.W., Evans, A., Fox, P., Lancaster, J., 1995. A probabilistic atlas of the human
5 brain: theory and rationale for its development. The International Consortium for Brain Mapping
6 (ICBM). Neuroimage.

7 McGlynn, S.M., Schacter, D.L., 1989. Unawareness of deficits in neuropsychological syndromes. J.
8 Clin. Exp. Neuropsychol. Off. J. Int. Neuropsychol. Soc.
9 <https://doi.org/10.1080/01688638908400882>

10 McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R., Kawas, C.H., Klunk, W.E.,
11 Koroshetz, W.J., Manly, J.J., Mayeux, R., Mohs, R.C., Morris, J.C., Rossor, M.N., Scheltens, P.,
12 Carrillo, M.C., Thies, B., Weintraub, S., Phelps, C.H., 2011. The diagnosis of dementia due to
13 Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's
14 Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement.
15 <https://doi.org/10.1016/j.jalz.2011.03.005>

16 Mimura, M., Yano, M., 2006. Memory Impairment and Awareness of Memory Deficits in Early-Stage
17 Alzheimer's Disease. Rev. Neurosci. <https://doi.org/10.1515/revneuro.2006.17.1-2.253>

18 Minoshima, S., Giordani, B., Berent, S., Frey, K.A., Foster, N.L., Kuhl, D.E., 1997. Metabolic
19 reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol.
20 <https://doi.org/10.1002/ana.410420114>

21 Montagne, A., Barnes, S.R., Sweeney, M.D., Halliday, M.R., Sagare, A.P., Zhao, Z., Toga, A.W.,
22 Jacobs, R.E., Liu, C.Y., Amezcu, L., Harrington, M.G., Chui, H.C., Law, M., Zlokovic, B. V.,
23 2015. Blood-Brain barrier breakdown in the aging human hippocampus. Neuron 85, 296–302.
24 <https://doi.org/10.1016/j.neuron.2014.12.032>

25 Montagne, A., Nation, D.A., Sagare, A.P., Barisano, G., Sweeney, M.D., Chakhoyan, A., Pachicano,
26 M., Joe, E., Nelson, A.R., D'Orazio, L.M., Buennagel, D.P., Harrington, M.G., Benzinger,
27 T.L.S., Fagan, A.M., Ringman, J.M., Schneider, L.S., Morris, J.C., Reiman, E.M., Caselli, R.J.,
28 Chui, H.C., Tcw, J., Chen, Y., Pa, J., Conti, P.S., Law, M., Toga, A.W., Zlokovic, B. V., 2020.
29 APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline. Nature 581, 71–76.
30 <https://doi.org/10.1038/s41586-020-2247-3>

31 Mori, S., Wakana, S., Van Zijl, P.C.M., Nagae-Poetscher, L.M., 2005. MRI atlas of human white
32 matter. Elsevier.

33 Nation, D.A., Sweeney, M.D., Montagne, A., Sagare, A.P., D'Orazio, L.M., Pachicano, M.,
34 Sepehrband, F., Nelson, A.R., Buennagel, D.P., Harrington, M.G., Benzinger, T.L.S., Fagan,
35 A.M., Ringman, J.M., Schneider, L.S., Morris, J.C., Chui, H.C., Law, M., Toga, A.W., Zlokovic,
36 B. V., 2019. Blood–brain barrier breakdown is an early biomarker of human cognitive
37 dysfunction. Nat. Med. 25, 270–276. <https://doi.org/10.1038/s41591-018-0297-y>

38 Nilsson, M., Lätt, J., Van Westen, D., Brockstedt, S., Lasič, S., Ståhlberg, F., Topgaard, D., 2013.
39 Noninvasive mapping of water diffusional exchange in the human brain using filter-exchange
40 imaging. Magn. Reson. Med. 69, 1573–1581. <https://doi.org/10.1002/mrm.24395>

41 Ohene, Y., Harrison, I.F., Nahavandi, P., Ismail, O., Bird, E. V., Ottersen, O.P., Nagelhus, E.A.,
42 Thomas, D.L., Lythgoe, M.F., Wells, J.A., 2019. Non-invasive MRI of brain clearance pathways
43 using multiple echo time arterial spin labelling: an aquaporin-4 study. Neuroimage.
44 <https://doi.org/10.1016/j.neuroimage.2018.12.026>

1 Pardilla-Delgado, E., Torrico-Teave, H., Sanchez, J.S., Ramirez-Gomez, L.A., Baena, A., Bocanegra,
2 Y., Vila-Castelar, C., Fox-Fuller, J.T., Guzmán-Vélez, E., Martínez, J., Alvarez, S., Ochoa-
3 Escudero, M., Lopera, F., Quiroz, Y.T., 2021. Associations between subregional thalamic
4 volume and brain pathology in autosomal dominant Alzheimer's disease. *Brain Commun.*
5 <https://doi.org/10.1093/braincomms/fcab101>

6 Pierpaoli, C., Walker, L., Irfanoglu, M.O., Barnett, A., Basser, P., Chang, L.C., Koay, C., Pajevic, S.,
7 Rohde, G., Sarlls, J., 2010. TORTOISE: an integrated software package for processing of
8 diffusion MRI data, in: ISMRM 18th Annual Meeting. Stockholm.

9 Sagare, A.P., Sweeney, M.D., Makshanoff, J., Zlokovic, B. V., 2015. Shedding of soluble platelet-
10 derived growth factor receptor- β from human brain pericytes. *Neurosci. Lett.*
11 <https://doi.org/10.1016/j.neulet.2015.09.025>

12 Salmon, E., Perani, D., Herholz, K., Marique, P., Kalbe, E., Holthoff, V., Delbeuck, X., Beuthien-
13 Baumann, B., Pelati, O., Lespagnard, S., Collette, F., Garraux, G., 2006. Neural correlates of
14 anosognosia for cognitive impairment in Alzheimer's disease. *Hum. Brain Mapp.*
15 <https://doi.org/10.1002/hbm.20203>

16 Scola, E., Bozzali, M., Agosta, F., Magnani, G., Franceschi, M., Sormani, M.P., Cercignani, M.,
17 Pagani, E., Falautano, M., Filippi, M., Falini, A., 2010. A diffusion tensor MRI study of patients
18 with MCI and AD with a 2-year clinical follow-up. *J. Neurol. Neurosurg. Psychiatry* 81, 798–
19 805. <https://doi.org/10.1136/jnnp.2009.189639>

20 Sengillo, J.D., Winkler, E.A., Walker, C.T., Sullivan, J.S., Johnson, M., Zlokovic, B. V., 2013.
21 Deficiency in mural vascular cells coincides with blood-brain barrier disruption in alzheimer's
22 disease. *Brain Pathol.* <https://doi.org/10.1111/bpa.12004>

23 Sweeney, M.D., Sagare, A.P., Zlokovic, B. V., 2018. Blood-brain barrier breakdown in Alzheimer
24 disease and other neurodegenerative disorders. *Nat. Rev. Neurol.*
25 <https://doi.org/10.1038/nrneurol.2017.188>

26 Takahashi, H., Ishii, K., Kashiwagi, N., Watanabe, Y., Tanaka, H., Murakami, T., Tomiyama, N.,
27 2017. Clinical application of apparent diffusion coefficient mapping in voxel-based morphometry
28 in the diagnosis of Alzheimer's disease. *Clin. Radiol.* <https://doi.org/10.1016/j.crad.2016.11.002>

29 Toledo, J.B., Arnold, S.E., Raible, K., Brettschneider, J., Xie, S.X., Grossman, M., Monsell, S.E.,
30 Kukull, W.A., Trojanowski, J.Q., 2013. Contribution of cerebrovascular disease in autopsy
31 confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre.
32 *Brain.* <https://doi.org/10.1093/brain/awt188>

33 van de Haar, H.J., Burgmans, S., Jansen, J.F.A., van Osch, M.J.P., van Buchem, M.A., Muller, M.,
34 Hofman, P.A.M., Verhey, F.R.J., Backes, W.H., 2017. Blood-Brain Barrier Leakage in Patients
35 with Early Alzheimer Disease. *Radiology.* <https://doi.org/10.1148/radiol.2017164043>

36 van de Haar, H.J., Jansen, J.F.A., van Osch, M.J.P., van Buchem, M.A., Muller, M., Wong, S.M.,
37 Hofman, P.A.M., Burgmans, S., Verhey, F.R.J., Backes, W.H., 2016. Neurovascular unit
38 impairment in early Alzheimer's disease measured with magnetic resonance imaging. *Neurobiol.*
39 *Aging* 45, 190–196. <https://doi.org/10.1016/j.neurobiolaging.2016.06.006>

40 Wang, H., Golob, E.J., Su, M.Y., 2006. Vascular volume and blood-brain barrier permeability
41 measured by dynamic contrast enhanced MRI in hippocampus and cerebellum of patients with
42 MCI and normal controls. *J. Magn. Reson. Imaging* 24, 695–700.
43 <https://doi.org/10.1002/jmri.20669>

44 Wang, J., Fernández-Seara, M.A., Wang, S., St Lawrence, K.S., 2007. When perfusion meets diffusion:

1 In vivo measurement of water permeability in human brain. *J. Cereb. Blood Flow Metab.*
2 <https://doi.org/10.1038/sj.jcbfm.9600398>

3 Yu, J., Li, J., Huang, X., 2012. The Beijing version of the montreal cognitive assessment as a brief
4 screening tool for mild cognitive impairment: A community-based study. *BMC Psychiatry*.
5 <https://doi.org/10.1186/1471-244X-12-156>

6 Zhang, C.E., Wong, S.M., Uiterwijk, R., Backes, W.H., Jansen, J.F.A., Jeukens, C.R.L.P.N., van
7 Oostenbrugge, R.J., Staals, J., 2019. Blood–brain barrier leakage in relation to white matter
8 hyperintensity volume and cognition in small vessel disease and normal aging. *Brain Imaging*
9 *Behav.* 13, 389–395. <https://doi.org/10.1007/s11682-018-9855-7>

10 Zhu, G., Federau, C., Wintermark, M., Chen, H., Marcellus, D.G., Martin, B.W., Heit, J.J., 2020.
11 Comparison of MRI IVIM and MR perfusion imaging in acute ischemic stroke due to large
12 vessel occlusion. *Int. J. Stroke*. <https://doi.org/10.1177/1747493019873515>

13 Zlokovic, B. V., 2008. The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders.
14 *Neuron*. <https://doi.org/10.1016/j.neuron.2008.01.003>

15